ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer

In the case of primary surgery, in patients with sentinel node involvement, it has already been shown that omitting axillary lymph node dissection (ALND), often combining axillary radiotherapy (RT), does not worsen the prognosis and does significantly reduce the appearance of lymphedema. However, patients who have received neoadjuvant systemic treatment cannot benefit from this option, even though in the majority of those who have responded well to treatment, a residual disease in the armpit is low, but there are no studies yet published that supports the possibility of not performing lymphade

Trial Details

NCT ID
NCT04889924
Phase
NA
Sponsor
Hospital Universitari de Bellvitge
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Axillary Radiotherapy
  • Lymphadenectomy
Locations (sample)
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Sydney, New South Wales, Australia|-33.86785,151.20732
  • Badalona, Barcelona, Spain|41.45004,2.24741
  • Mataró, Barcelona, Spain|41.54211,2.4445
  • Barakaldo, Bizkaia, Spain|43.29639,-2.98813

Key Eligibility Criteria

  • T1-T4 N0/ T0-T4 N1 at diagnosis and subsidiary of neoadjuvant treatment
  • Post-CT SLN with ≤2 macrometastasis/micrometastasis or ITCs
  • Post-CT axillary response by ultrasound or MRI
  • Complete at least 70% of neoadjuvant chemotherapy and 6 months of endocrine treatment.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →